138 related articles for article (PubMed ID: 35223529)
1. Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement.
Zhou N; Li T; Liang M; Ren F; Ni H; Liu W; Shi T; Xu D; Chen Q; Yu H; Song Z; Zu L; Li S; Xu S
Front Oncol; 2022; 12():848779. PubMed ID: 35223529
[TBL] [Abstract][Full Text] [Related]
2. Use of on-therapy ctDNA monitoring in a patient with
Yeung V; Kim C; Kiedrowski LA; Liu SV; Reuss JE
Transl Lung Cancer Res; 2022 Jan; 11(1):111-116. PubMed ID: 35242632
[TBL] [Abstract][Full Text] [Related]
3. Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report.
Bi Y; Xia C; Zhang X; Liu H
Oncol Lett; 2023 Sep; 26(3):407. PubMed ID: 37600327
[TBL] [Abstract][Full Text] [Related]
4. Pralsetinib for the treatment of a
Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
[TBL] [Abstract][Full Text] [Related]
5. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
6. Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with
An L; Chen P; Wang J; Qin X; Liu T; Gao Y; Wang P; Zhang D; Fang X; Zhang Z
Front Oncol; 2022; 12():1024365. PubMed ID: 36568233
[TBL] [Abstract][Full Text] [Related]
7. Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report.
Zhao S; Zhu S; Lei X; Xu D; Shi T; Chen Q; Ren F; Chen G; Huang D; Xu S
Thorac Cancer; 2021 Oct; 12(20):2815-2818. PubMed ID: 34405544
[TBL] [Abstract][Full Text] [Related]
8. Current management of
Stinchcombe TE
Ther Adv Med Oncol; 2020; 12():1758835920928634. PubMed ID: 32782485
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage
Goldman JW; Sholl LM; Dacic S; Fishbein MC; Murciano-Goroff YR; Rajaram R; Szymczak S; Szpurka AM; Chao BH; Drilon A
Front Oncol; 2023; 13():1178313. PubMed ID: 37274265
[TBL] [Abstract][Full Text] [Related]
10. Pralsetinib for the treatment of non-small cell lung cancer.
Fu XY; Dong XD; Zeng L; Ashby CR; Chen ZS; Cheng C
Drugs Today (Barc); 2021 Sep; 57(9):559-569. PubMed ID: 34586104
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring
Fu M; Feng CM; Xia DQ; Ji ZM; Xia HL; Hu NN; Leng ZJ; Xie W; Fang Y; Cao LJ; Zhang JQ
Front Oncol; 2022; 12():954886. PubMed ID: 36052259
[No Abstract] [Full Text] [Related]
12. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
Lee YP; Jeong BH; Eun Y; Kang CI; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Eur J Cancer; 2021 Dec; 159():167-173. PubMed ID: 34753013
[TBL] [Abstract][Full Text] [Related]
13. Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.
Wang SS; Wang F; Zeng Z; Gao F; Liu HH; Wang HN; Hu Y; Qin HF
Front Oncol; 2022; 12():929763. PubMed ID: 36226049
[TBL] [Abstract][Full Text] [Related]
14. A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring
Qin H; Wan Y; Dong Y; Sun Q
Cancer Manag Res; 2023; 15():765-769. PubMed ID: 37525669
[TBL] [Abstract][Full Text] [Related]
15. The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.
Fu S; Liang Y; Lin YB; Wang F; Huang MY; Zhang ZC; Wang J; Cen WJ; Shao JY
PLoS One; 2015; 10(4):e0124354. PubMed ID: 25905642
[TBL] [Abstract][Full Text] [Related]
16. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
17. Non-small-cell lung cancer: how to manage
Andrini E; Mosca M; Galvani L; Sperandi F; Ricciuti B; Metro G; Lamberti G
Drugs Context; 2022; 11():. PubMed ID: 35912003
[TBL] [Abstract][Full Text] [Related]
18. Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition.
Barsouk A; Elghawy O; Stone S; Singh A
Anticancer Drugs; 2024 Apr; ():. PubMed ID: 38696710
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC).
Zhang Q; Xu C; Wang W; Wu M; Zhu Y; Zhuang W; Du K; Huang Y; Chen Y; Wu B
Med Sci Monit; 2018 Nov; 24():8207-8212. PubMed ID: 30429449
[TBL] [Abstract][Full Text] [Related]
20. RET Inhibitors in Non-Small-Cell Lung Cancer.
Cascetta P; Sforza V; Manzo A; Carillio G; Palumbo G; Esposito G; Montanino A; Costanzo R; Sandomenico C; De Cecio R; Piccirillo MC; La Manna C; Totaro G; Muto P; Picone C; Bianco R; Normanno N; Morabito A
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
